Copy-number intratumor heterogeneity as high-risk feature of stage II colon cancer<sup>†</sup>.

Authors:
van den Bosch T; Miedema DM; Vermeulen L.

Journal:
J Pathol

Publication Year: 2022

DOI:
10.1002/path.5919

PMCID:
PMC9544760

PMID:
35470895

View on PubMed View on PMC View Publisher
Journal Information

Full Title: J Pathol

Abbreviation: J Pathol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pathology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Loss of the crumbs cell polarity complex disrupts epigenetic transcriptional control and cell cycle…
Owen N; Toms M; Tian Y and 7 more (2023) - Transparency Score: 4/6
A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis i…
Posner A; Prall OW; Sivakumaran T and 31 more (2022) - Transparency Score: 3/6
An overview of mutational and copy number signatures in human cancer.
Steele CD; Pillay N; Alexandrov LB. (2022) - Transparency Score: 3/6
Automated detection of vascular remodeling in tumor-draining lymph nodes by the deep-learning tool …
Bekkhus T; Avenel C; Hanna S and 6 more (2022) - Transparency Score: 5/6
Cancer-associated fibroblasts in pancreatic cancer: new subtypes, new markers, new targets.
Menezes S; Okail MH; Jalil SMA and 2 more (2022) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of interest statement: LV received consultancy fees from Bayer, MSD, Genentech, Servier and Pierre Fabre, but these had no relation to the content of this publication."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025